From JPMA On assuming the position of Chairman -Aiming to be a country where innovation is vibrant
The coronavirus disaster that lasted for three years had a major impact on social life, but thanks to the efforts of many healthcare professionals and the vaccines and therapeutic agents for new coronavirus infection (COVID-19), life before coronas has finally returned. During this period, new ways of working and living have become possible through the use of various digital tools, and in this respect, the coronary disaster seems to have changed the common sense of society.
On the other hand, the lessons we have learned from the coronary disaster are that medicines and vaccines are indispensable in the fight against pandemics, and that measures must be taken even in times of peace from the perspective of national security. In addition to pandemic countermeasures, there are many diseases for which there is still no cure, and pharmaceutical companies must work to create new medicines for these diseases.
The Pharmaceutical Manufacturers' Association of Japan (PMAJ) is committed not only to supporting academia and start-ups, but also to playing a role in nurturing the seeds generated through these activities, leading to the creation of new medicines originating from Japan. If, with the strong support of the government, each player establishes industry-academia-government collaboration from a new perspective with a strong will, drug discovery in Japan will accelerate and innovation will flourish.
Japan Pharmaceutical Manufacturers Association
Chairman Hiroaki Ueno
In order for innovation to continue to be generated, it is also important to have a system in which innovation is properly evaluated. This is important not only to encourage the creation of innovation in one's own country, but also to attract innovation from other countries. The Pharmaceutical Manufacturers Association of Japan (PMAJ) is committed to exchanging opinions with stakeholders and proposing policies that will help create a system in which the value of pharmaceutical products is properly evaluated.
We aim to create a "country where innovation thrives" where motivated companies take on the challenge of addressing unmet needs, innovation is continuously generated, and the value of pharmaceuticals produced is duly evaluated.
(Excerpt from the Chairman's Message on the website of the Pharmaceutical Manufacturers Association of Japan)
Japan Pharmaceutical Manufacturers Association (JPMA)
Japan Pharmaceutical Manufacturers Association (JPMA)
Founded in 1968, the Pharmaceutical Manufacturers Association of Japan (PMAJ) is a voluntary association of R&D-oriented pharmaceutical companies that has contributed to global healthcare through the development of innovative new ethical drugs under the motto "Realization of Patient Participatory Medicine".
The Pharmaceutical Manufacturers Association of Japan (PMAJ) is engaged in a multifaceted program of activities to solve various problems common to the pharmaceutical industry, to deepen understanding of pharmaceuticals, and to promote international collaboration. In addition, we are committed to the sound development of the pharmaceutical industry, particularly by strengthening our policy formulation and advocacy activities, addressing internationalization, and reinforcing our public relations system.
Aiming to contribute to society through the development of new drugs Japan Pharmaceutical Manufacturers Association